This week, the Federal Trade Commission halted its lawsuit against pharmacy-benefit managers CVS Caremark (CVS), Express Scripts (CI), and Optum (UNH) over insulin prices after President Donald Trump fired two of the agency’s commissioners, the Wall Street Journal’s Dave Michaels and Joseph Walker report. The agency said it needs to pause the litigation because no current commissioners can participate in the case, the authors note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- BofA says Hims & Hers Zepbound sales will be ‘immaterial’
- Health insurers received duplicate payments for Medicaid patients, WSJ reports
- CVS Health price target raised to $74 from $72 at Piper Sandler
- Moderately bullish options flow in CVS Health trading today
- Unusually active option classes on open March 18th